1 MALAT1 Expression is Associated with Aggressive Behavior in Indolent B-

2 Cell Neoplasms

Elena María Fernández-Garnacho¹, Ferran Nadeu^{1,2}, Silvia Martín¹, Pablo Mozas^{1,3},
Andrea Rivero^{1,3}, Julio Delgado^{1,2,3}, Eva Giné^{1,2,3}, Armando López-Guillermo^{1,2,3}, Martí
Duran-Ferrer¹, Itziar Salaverria^{1,2}, Cristina López^{1,2}, Sílvia Beà^{1,2,3}, Santiago Demajo¹,
Pedro Jares^{1,2,3}, Xose S Puente^{2,4}, José Ignacio Martín-Subero^{1,2,5}, Elias Campo^{1,2,3,5}, Lluís
Hernández^{1,2*}

8

¹Lymphoid Neoplasm Program, Institut d'Investigacions Biomèdiques August Pi I Sunyer
(IDIBAPS), Barcelona, Spain. ²Centro de Investigación Biomédica en Red de Cáncer
(CIBERONC), Madrid, Spain. ³Hospital Clínic of Barcelona, Universitat de Barcelona,
Barcelona, Spain.⁴University of Oviedo, Oviedo, Spain. ⁵Institució Catalana de Recerca i
Estudis Avançats (ICREA), Barcelona, Spain.

- 14
- 15

16 Abstract

17 MALAT1 is a long non-coding RNA with oncogenic roles in cancer but poorly studied in indolent B-cell neoplasms. Here, MALAT1 expression was analyzed using RNA-18 seq, microarrays or gRT-PCR in primary samples from various clinico-biological subtypes 19 20 of chronic lymphocytic leukemia (CLL, n=266) and follicular lymphoma (FL, n=61). In peripheral blood (PB) CLL samples, high MALAT1 expression was associated with a 21 22 significantly shorter time to treatment, independently from other known prognostic factors, 23 such as IGHV mutational status. Coding genes whose expression levels were associated with MALAT1 in CLL were predominantly related to oncogenic pathways stimulated in the 24 lymph node (LN) microenvironment. Further analysis of MALAT1 expression by 25 microarrays in paired CLL samples from PB/LN showed that its levels were maintained 26 between both anatomical compartments, supporting that the clinical value of MALAT1 27 28 expression found in PB is mirroring expression differences already present in LN. Similarly, high *MALAT1* expression in FL predicted for a shorter progression-free survival, 29 and its correlated expressed genes were associated with pathways promoting FL 30 31 pathogenesis. In summary, MALAT1 expression is related to pathophysiology and clinical 32 behavior of indolent B-cell neoplasms. Particularly in CLL its levels could be a surrogate 33 marker of the microenvironment stimulation and may contribute to refine the clinical 34 management of these patients.

35 *Keywords*: long non-coding RNAs, MALAT1, Lymphomas, CLL, FL, Biomarker.

*Corresponding Author: Lluís Hernández, Institut d'Investigacions Biomèdiques August
 Pi I Sunyer (IDIBAPS), Centre Esther Koplowitz (CEK), Rosselló 153, Barcelona 08036,
 Spain. Phone: 34-93-2275400, ext.4582; Fax: 34-93-2275717; orcid.org/0000-0002-4854 3069

40 E-mail: hernan@recerca.clinic.cat

41 Introduction

42 Long non-coding RNAs (IncRNAs) regulate the expression of protein-coding genes and are increasingly described as key players in physiological and pathological conditions, 43 most remarkably in cancer^{1,2}. One of the lncRNAs most frequently related to oncogenesis 44 45 is MALAT1, which has been implicated in the regulation of key cellular pathways such as MAPK/ERK, PI3K/AKT, WNT/B-catenin, and NF-kB³ and, as a consequence, involved in 46 many cancer-associated processes such as cell proliferation, migration, invasion, 47 apoptosis and angiogenesis⁴. There are also several studies supporting MALAT1 48 expression as a clinical biomarker mainly associated with a poor prognosis in solid 49 50 tumors³, although in some neoplasms such as diffuse large B-cell lymphoma (DLBCL), 51 colorectal and breast cancer, high levels of MALAT1 have been linked to a favorable outcome⁵⁻⁸. 52

53

54 In B-cell non-Hodgkin lymphomas (B-NHL), we and others have previously shown 55 that IncRNA deregulation is associated with immune cell-related functions and cell proliferation control^{9,10}. In the case of MALAT1, its expression has been shown to be 56 upregulated in some lymphoid neoplasms such as DLBCL¹¹, chronic lymphocytic leukemia 57 (CLL)¹², and mantle cell lymphoma (MCL)¹³. These results suggest that MALAT1 58 expression could be associated with poor prognosis even in indolent B-NHL, but most of 59 these studies include relatively few cases and the possible clinical relevance of MALAT1 60 61 expression in these lymphoid neoplasms is still not well known. In this study, we have 62 performed a detailed characterization of the biological and clinical impact of MALAT1 deregulation in two types of indolent B cell lymphomas with different underlying 63 pathobiological mechanisms, namely CLL and follicular lymphoma (FL). 64

65

67 Material and methods

68 **Description of the transcriptional data and patient cohorts**

69 This study exploited previously published genome wide transcriptional data from 70 CLL and FL. Regarding CLL, we reanalyzed our RNA-seq data from peripheral blood (PB) samples obtained from 266 patients, and 25 additional monoclonal B cell lymphocytosis 71 72 donors (MBL) of the Spanish ICGC consortium with full clinical annotations¹⁴. We have 73 also analyzed the microarray data from the GSE21029 GEO dataset, including 17 patients with paired PB and lymph node (LN) samples and 7 additional samples from PB¹⁵. For the 74 75 analysis of MALAT1 in FL, we extracted RNA from formalin-fixed paraffin-embedded 76 (FFPE) LN samples of 61 FL patients (stages 1 to 3A) from the Hematopathology 77 collection of the Biobank of the Hospital Clínic de Barcelona-IDIBAPS (Spain). In addition, 78 microarray data generated from sorted FL neoplastic cells of 23 patients were obtained from the GSE107367 GEO dataset¹⁶. 79

80

81 RNA extraction and qRT-PCR

For the 61 FFPE FL samples, 3-10 cuts of 10μm each were used per sample for RNA extraction using Allprep DNA/RNA FFPE kit (Qiagen). RNA integrity was analyzed with TS4200 using DV200 index as recommended by the manufacturer (Agilent). In this way, samples with DV200 less than 35% were excluded to avoid excessive degraded material. Reverse transcriptase reaction was performed using High-Capacity Reverse transcription kit (Applied Biosystems) with an RNA input of 90 ng.

88

MALAT1 expression was analyzed by qRT-PCR using a short amplicon specifically designed for FFPE samples. *MALAT1* expression levels were normalized using three reference genes (*ACTB*, *GAPDH* and *YWHAZ*) which have been previously used in B-cell

92	lymphomas, including FL samples ^{17,18} . Primer quantities were optimized for each amplic	on
93	to reach a high efficiency (range: 90-96%) and their sequences were:	5'-
94	CCCCTTCCCTAGGGGATTTCA-3' (MALAT1 forward),	5'-
95	AAGCCCACAGGAACAAGTCC-3' (MALAT1 reverse), 5'- CCAACCGCGAGAAGATGA	C-
96	3'(ACTB forward), 5'-TAGCACAGCCTGGATAGCAA-3' (ACTB reverse),	5'-
97	AGGTGAAGGTCGGAGTCA-3'(GAPDH forward),	5'
98	CAACAATATCCACTTTACCAGAGTTAA-3' (GAPDH reverse),	5'-
99	CAAAGACAGCACGCTAATAATGCA-3' (YWHAZ forward), and	5'-
100	TCAGCTTCGTCTCCTTGGGTA-3' (YWHAZ reverse). Amplification reactions were carrie	ed
101	out using PowerUp [™] SYBR [™] Green Master Mix (Applied Biosystems, Foster City, C	A)
102	following supplier's recommendations in a Step One Plus thermocycler (Appli	ed
103	Biosystems). Transcript expression relative quantification was performed referred to	а
104	calibrator sample of universal human reference RNA (Invitrogen).	

105

106 Bioinformatic analyses and statistics

107 Microarray data were normalized with RMA-based methodology and used to 108 analyze the expression levels of *MALAT1* transcript. Although the expression microarrays 109 were enriched in probe sets for coding genes, several probe sets that hybridize exclusively 110 to the MALAT1 transcript were initially included. The specificity of the probe sets was 111 confirmed in the Affymetrix database (NettAffx[™]). Only one probe set was excluded 112 (223579_s_at) at this stage. The correlations among the different probe sets were checked by strand and another probe set was excluded as an outlier (224559 at). Finally, the mean 113 114 values of the remaining probe sets were retained as reliable for measuring the expression 115 levels of MALAT1 (probe sets 1558678_s_at, 223940_x_at, 224558_s_at, 224567_x_at, 116 224568_x_at and 226675_s_at).

117

To identify potential target genes, ranked lists of coding genes according to the 118 119 degree of Pearson's correlation to MALAT1 were obtained for the different indolent B-cell 120 lymphomas under study using either RNA-seq or microarray data. Only those statistically 121 significant correlations after correction for multiple comparisons (adjusted p-value<0.05) were considered for the downstream analyses. We separately analyzed positive and 122 123 negative correlations of coding genes with MALAT1 using the webtool Metascape¹⁹. The 124 Metascape output of enriched (Reactome) pathways were obtained as tables, and 125 summary plots depicting relevant pathways with very high statistical significance (q<0.05) 126 were prepared with Graphpad Prism v7. Furthermore, we used Gene Set Enrichment 127 Analysis (GSEA v3.0 from http://www.gsea-msigdb.org) to perform additional pathway 128 enrichment analyses in CLL using the C2 curated gene signatures from MSigDB/GSEA 129 website and several specific signatures previously related to differences between LN and PB in CLL ²⁰. Only statistically significant signatures with NES higher than 2 as absolute 130 131 value were considered as potentially relevant.

132 In the clinical association studies, optimal cut-off points for MALAT1 expression 133 groups were obtained using the maxstat algorithm which optimized the log-rank statistics 134 (maxstat package, R Software, Vienna). Cumulative incidence and Kaplan-Meier curves, 135 scatterplots, and box plot graphs were generated using both the R environment and 136 GraphPad Prism v7. Univariate and multivariate Fine-Grav regression models considering 137 MALAT1 as a continuous variable (as a more stringent statistical approach) were used for 138 measuring its impact on time to treatment (TTT). Univariate analysis of MALAT1 as a 139 continuous variable was performed with the Cox regression model for overall survival 140 (OS). Both calculations were performed with R v.4.0.3. Student's t-test was used to 141 evaluate the differences in the mean expression of MALAT1 among subtypes and

molecular factors with previously described prognostic value in CLL. Paired t-test was used to evaluate differences in *MALAT1* expression between paired samples of CLL in PB and LN^{15} . Linear regression on scatter plots was representing the correlation between *MALAT1* expression and the epiCMIT score (epigenetically-determined Cumulative MIToses)²¹.

148 Results

149 MALAT1 expression in CLL

We initially evaluated the expression levels of *MALAT1* in CLL and MBL patients. *MALAT1* expression was significantly higher in CLL than in MBL (P<0.001) (Fig. 1A). We also stratified *MALAT1* levels according to the IGHV mutational status (mutated vs nonmutated) and epigenetic subtypes (naïve-like, memory-like and intermediate) and no significant differences were observed among the different groups (Fig. 1A).

155

We next evaluated whether MALAT1 expression was associated with the clinical 156 157 behavior of the tumor. Using the *maxstat* algorithm, we segregated CLL patients into high 158 and low expression groups (Fig. S1A). Patients with high MALAT1 expression (N=65) had 159 a significantly shorter time to treatment (TTT) than the MALAT1-low group (N=201) (p<0.0001) (Fig. 1B). This finding was also confirmed in the subset of patients clinically 160 161 classified as Binet A (N=239, 57 with high and 182 low MALAT1 levels) (P=0.0003) (Fig. 162 S2A). On the contrary, MALAT1 levels were not related to the overall survival (OS) of the 163 patients (Fig. S1B and Fig. S2B). The adverse impact of high MALAT1 expression on TTT 164 was further confirmed in IGHV-mutated CLL and in the three epigenetic CLL subtypes 165 (Figure 1B). Similar findings were observed when the analyses were restricted to patients 166 with Binet A CLL (Fig. S2C-S2D). To evaluate the independent prognostic impact of 167 MALAT1, we performed multivariate regression models. First, we checked that MALAT1 168 as a continuous isolated variable also had significant prognostic value for TTT (HR=1.32; 169 95%CI: 1.18-1.48); p<0.0001) but not for OS (HR = 1.05; 95%CI: 0.89-1.24; p=0.561). Next, the multivariate analyses confirmed that MALAT1 expression also had an 170 171 independent prognostic value for TTT considering Binet stage and the IGHV mutational status (P=0.0004) and Binet stage and the epigenetic subgroups (P<0.0001) (Fig. 2A). We 172

also evaluated the possible association of *MALAT1* levels with other molecular factors
previously shown to have prognostic value in CLL, such as mutations in driver genes,
number of chromosomal aberrations^{14,22}, IGLV3-21 variant/R110 mutation²³, or the DNA
methylation-based epiCMIT score related to the proliferative history of the tumor cells²¹. *MALAT1* expression levels were not related to any of these variables (Fig. S3 and Fig.S4).
Overall, these data indicate that *MALAT1* expression has a prognostic value for TTT in
CLL irrespective of other known genetic and epigenetic prognostic parameters.

180

To determine whether *MALAT1* deregulation could be related to genetic alterations, we analyzed the gene mutational status in the whole-genome sequences of 150 cases from the ICGC Consortium¹⁴. Only five CLL and one MBL revealed mutations in the *MALAT1* locus and were not related to the expression of the gene (Table S1A). No copy number alterations affecting 11q13, where *MALAT1* is located, were found, whereas only 2 CLL cases had copy number neutral loss of heterozygosity. None of these alterations were related to the expression of the gene (Table S1B).

188

To evaluate the possible functional implications of MALAT1 expression we 189 190 searched for coding genes that were significantly correlated, either positively or negatively, 191 with MALAT1 in the different CLL subgroups (Table S2) and we subsequently performed 192 pathway enrichment analyses. Among the positively correlated genes, the significantly 193 selected pathways were remarkably associated with functions related to activation, 194 proliferation, and survival of CLL cells in the LN microenvironment (Fig. 2B, Fig. S5, Table 195 S3 and Table S4). These pathways included general cell proliferation-related functions such as signaling by PI3K/AKT, MAPK, IL10 and IL4, among others²⁴⁻²⁹. As these results 196 197 pointed to a possible influence of microenvironment stimuli in MALAT1 expression we used GSEA to analyze CLL specific signatures and finding, both in U-CLL and M-CLL, 198

significant positive enrichments in a signature of genes previously described as significantly upregulated in LN vs. PB (Fig. 3B)²⁰. Finally, we also analyzed previously published microarray data of paired LN and PB CLL samples¹⁵, where we found that *MALAT1* levels did not change significantly between LN and PB (P=0.097) (Fig. 3C). All these results suggest that the relationship between *MALAT1* expression and shorter TTT that we have observed in PB samples could represent a surrogate biomarker for the degree of stimulation and proliferation of CLL cells in the LN.

206

207 MALAT1 expression in Follicular Lymphoma

Based on the results of MALAT1 in CLL and its potential association with the LN 208 209 microenvironment, we further explored the role of MALAT1 in FL, another indolent B cell 210 lymphoid neoplasm with predominant nodal presentation. MALAT1 expression levels were 211 analyzed by gRT-PCR in a series of 61 grade 1-3A FL. These patients had been 212 homogenously treated with R-CHOP. Using the maxstat algorithm, we identified two 213 groups of FL with high (N=11) and low (N=50) MALAT1 expression. The clinical, biological, 214 and histological characteristics, including histological grade, were similar in both 215 subgroups (Table S5). FL cases with high MALAT1 expression had a significantly shorter 216 progression-free survival (PFS) than cases with low expression (P=0.017) (Fig. 4A). 217 However, no significant differences were observed in transformation to DLBCL or OS 218 between cases with low and high expression (P=0.088 and P=0.0177) (Fig. S6).

219

To explore the possible biological role of *MALAT1* expression in FL we reanalyzed microarray expression data previously generated on purified FL B-cells¹⁶. We observed that the coding genes positively correlating with *MALAT1* expression (Table S6) were associated with cell proliferation and other pathways like VEGF, MAPK, interleukin signaling (including some particular pathways related with IL-3 and IL-5) and BCR

signaling, also described as involved in FL oncogenesis (Fig. 4B and Table S7)^{30,31}. Moreover, among the genes positively correlated with *MALAT1* involved in BCR signaling we noticed *PIK3CD* that it has been previously described as predictor of poor prognosis in FL^{32} .

229 Finally, we performed a comparison of all genes involved in pathways significantly 230 enriched in FL and compared to those found in CLL (considering together U-CLL and M-231 CLL gene lists). A large proportion of those genes were exclusive for each lymphoma type (88% in FL and 99% in CLL) (Fig. S7 and Table S8). Concordantly, cell cycle-related or 232 233 MAPK pathways that were initially observed in both neoplasms involved different sets of 234 MALAT1 positively correlated genes (Tables S9 and Table S10). On the other hand, a total 235 of 12 genes were found in common in the comparative analysis, including several involved in cytokine and interleukin signaling (CAPZA1), cell cycle (GAR1), or both (HSP90AA1, 236 237 LMNB1 and LYN)(Table S11).

239 Discussion

240 In this report, we provide novel insights into the clinical and biological role of 241 MALAT1 in indolent B cell neoplasms. Our study revealed that MALAT1 upregulation was 242 associated with a detrimental clinical behavior in the different entities studied, associated 243 with a shorter TTT in CLL or shorter PFS in FL. Interestingly, MALAT1 upregulation was a 244 prognostic factor in CLL independently of the IGHV mutational status, epigenetic 245 subgroups, Binet stage or genetic alterations. In FL, MALAT1 overexpression was also associated with shorter progression-free survival although the clinical and biological 246 247 features of patients with low and high expression were similar.

248

We also studied the potential causes and consequences of *MALAT1* upregulation that might justify its clinical behavior in indolent B cell neoplasms. In CLL, *MALAT1* mutations were rare and not related to the expression of the gene. This finding is similar to those in other neoplasms such as bladder cancer, head and neck squamous cell cancer, and lung adenocarcinomas, in which single nucleotides variants and indels were found, although considered passenger events caused by a transcription-associated mutational process^{33,34}.

256

Therefore, other mechanisms should be related with *MALAT1* overexpression and, in fact, its promoter has been described in solid tumor models to be regulated by transcription factors as *HIF1* α and *STAT3*, which are induced by microenvironmental factors as hypoxia and cytokines/interleukins, respectively^{35–37}. In CLL, microenvironment stimulation occurs in the LN and is a key process for activation, proliferation and survival of these tumoral B cells³⁸. Interestingly, our guilt-by-association analysis on the coding genes correlated with *MALAT1* in PB CLL samples revealed significant enrichments in a gene

signature highly expressed in nodal CLL²⁰, as well as for interleukin-related signatures. On top of that, we found that *MALAT1* levels remain similar in PB compared to LN paired CLL samples, supporting that the clinical value of *MALAT1* expression found in PB is mirroring expression differences in LN associated with the degree of the microenvironment stimulation.

269

270 In FL, our study also revealed biological insights that seem to explain the clinical 271 behavior of MALAT1 upregulation in these neoplasms. In these tumors, coding genes 272 correlated with MALAT1 expression were enriched in cell cycle-related processes as well 273 as pathways related to cell proliferation, migration and angiogenesis, such as MAPK and 274 VEGF pathways, which have been previously linked to MALAT1 function in other tumor 275 models³⁹. We also found that cases with high *MALAT1* expression were significantly 276 associated with high levels of genes involved in BCR signaling and interleukin signaling, 277 such as LYN and PIK3CD, the expression of which promote cell growth and have been associated with poor prognosis in FL^{32,40}. In this regard, these are relevant associations 278 279 supporting our results about the clinical impact of MALAT1, even though our series 280 included a relative limited number of cases.

281

282 Finally, the comparison of MALAT1 associated pathways and the involved genes 283 showed a low degree of overlapping in the corresponding gene signatures, even in cell 284 cycle-related or MAPK pathways that were initially observed as enriched in both neoplasms. These results suggest that MALAT1 could be contributing to the regulation of 285 286 different transcriptional gene sets in both lymphomas. In spite of these differences at the 287 gene level, we also observed that processes as cell proliferation and MAPK pathways 288 were potentially commonly affected by MALAT1 upregulation, and thus could explain its 289 common clinical impact in both neoplasms.

291	In summary, these findings highlight that MALAT1 overexpression plays a role in
292	the pathobiology and clinical behavior of indolent B cell neoplasms and related with a more
293	aggressive behavior of patients with higher MALAT1 levels. Particularly in CLL, MALAT1
294	could serve as a clinical biomarker that seems to be a surrogate marker of the degree of
295	stimuli the CLL cells receive from the microenvironment. Therefore, MALAT1 expression
296	could be taken in account in further studies as complementary to other known prognostic
297	factors to improve the clinical management of these patients.
298	
299	
300	
301	
302	
303	
304	
305	
306	
307	
308	
309	
310	
311	
312	
313	
314	
315	

316

317 References

318

- 1. Huang, Y. et al. Regulatory long non-coding RNA and its functions. J. Physiol. Biochem. 68,
- 320 611–618 (2012).
- 321 2. Bhan, A., Soleimani, M. & Mandal, S. S. Long Noncoding RNA and Cancer: A New Paradigm.
- 322 *Cancer Res.* **77**, 3965–3981 (2017).
- 323 3. Li, Z.-X. *et al.* MALAT1: a potential biomarker in cancer. *Cancer Manag Res* **10**, 6757–6768
- 324 (2018).
- 4. Zhang, X., Hamblin, M. H. & Yin, K.-J. The long noncoding RNA Malat1: Its physiological and
- 326 pathophysiological functions. *RNA Biol* **14**, 1705–1714 (2017).
- 327 5. Wang, Y. *et al.* The Long Noncoding RNA MALAT-1 is A Novel Biomarker in Various Cancers: A
- 328 Meta-analysis Based on the GEO Database and Literature. J Cancer 7, 991–1001 (2016).
- 329 6. Lenz, G. et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359, 2313-
- 330 2323 (2008).
- 331 7. Kwok, Z. H., Roche, V., Chew, X. H., Fadieieva, A. & Tay, Y. A non-canonical tumor suppressive
- role for the long non-coding RNA MALAT1 in colon and breast cancers. Int J Cancer 143, 668–

333 678 (2018).

- Kim, J. *et al.* Long noncoding RNA MALAT1 suppresses breast cancer metastasis. *Nat Genet* 50,
 1705–1715 (2018).
- 336 9. Zhou, M. et al. Discovery and validation of immune-associated long non-coding RNA
- biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell
- 338 lymphoma. *Mol. Cancer* **16**, 16 (2017).

- 10. Roisman, A. *et al.* Differential expression of long non-coding RNAs are related to proliferation
- and histological diversity in follicular lymphomas. *Br J Haematol* **184**, 373–383 (2019).
- 341 11. Wang, Q.-M., Lian, G.-Y., Song, Y., Huang, Y.-F. & Gong, Y. LncRNA MALAT1 promotes
- 342 tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195. *Life*
- *Sci* **231**, 116335 (2019).
- 12. Ahmadi, A. et al. Altered expression of MALAT1 IncRNA in chronic lymphocytic leukemia
- 345 patients, correlation with cytogenetic findings. *Blood Res* 53, 320–324 (2018).
- 13. Wang, X. et al. LncRNA MALAT1 promotes development of mantle cell lymphoma by
- 347 associating with EZH2. *J Transl Med* **14**, 346 (2016).
- 348 14. Puente, X. S. et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature
- **526**, 519–524 (2015).
- 350 15. Herishanu, Y. et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-
- 351 kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. *Blood* **117**, 563–
- 352 574 (2011).
- 16. Pangault, C. et al. Follicular lymphoma cell niche: identification of a preeminent IL-4-
- dependent T(FH)-B cell axis. *Leukemia* **24**, 2080–2089 (2010).
- 355 17. Potashnikova, D., Gladkikh, A. & Vorobjev, I. A. Selection of superior reference genes'
- 356 combination for quantitative real-time PCR in B-cell lymphomas. *Ann Clin Lab Sci* **45**, 64–72
- 357 (2015).
- 18. Yagi, K. *et al.* Expression of multidrug resistance 1 gene in B-cell lymphomas: association with
- 359 follicular dendritic cells. *Histopathology* **62**, 414–420 (2013).
- 360 19. Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-
- 361 level datasets. *Nat Commun* **10**, 1523 (2019).

- 362 20. Dadashian, E. L. *et al.* TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only
- 363 Partially Inhibited by Ibrutinib. *Cancer Res* **79**, 360–371 (2019).
- 364 21. Duran-Ferrer, M. et al. The proliferative history shapes the DNA methylome of B-cell tumors
- 365 and predicts clinical outcome. *Nature Cancer* **1**, 1066–1081 (2020).
- 366 22. Quesada, V. et al. The genomic landscape of chronic lymphocytic leukemia: clinical
- 367 implications. *BMC Med* **11**, 124 (2013).
- 368 23. Nadeu, F. et al. IGLV3-21R110 identifies an aggressive biological subtype of chronic
- 369 lymphocytic leukemia with intermediate epigenetics. *Blood* **137**, 2935–2946 (2020).
- 370 24. Mittal, A. K. et al. Chronic lymphocytic leukemia cells in a lymph node microenvironment
- depict molecular signature associated with an aggressive disease. *Mol Med* **20**, 290–301
- 372 (2014).
- 373 25. Brocke-Heidrich, K. et al. Interleukin-6-dependent gene expression profiles in multiple
- 374 myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated
- 375 with Stat3 activation. *Blood* **103**, 242–251 (2004).
- 376 26. Kowalska, W. & Bojarska-Junak, A. Monocytic MDSC as a source of immunosuppressive
- 377 cytokines in chronic lymphocytic leukemia (CLL) microenvironment. Folia Histochem Cytobiol
- **58**, 25–36 (2020).
- 27. Mirabilii, S. *et al.* Biological Aspects of mTOR in Leukemia. *Int J Mol Sci* **19**, (2018).

380 28. Lezina, L. *et al.* CD40L/IL-4-stimulated CLL demonstrates variation in translational regulation of

- 381 DNA damage response genes including ATM. *Blood Adv* 2, 1869–1881 (2018).
- 382 29. Shukla, A., Shukla, V. & Joshi, S. S. Regulation of MAPK signaling and implications in chronic
- 383 lymphocytic leukemia. *Leuk Lymphoma* **59**, 1565–1573 (2018).
- 384 30. Devan, J., Janikova, A. & Mraz, M. New concepts in follicular lymphoma biology: From BCL2 to
- 385 epigenetic regulators and non-coding RNAs. *Semin Oncol* **45**, 291–302 (2018).

386	31. Duś-Szachniewicz, K., Rymkiewicz, G., Agrawal, A. K., Kołodziej, P. & Wiśniewski, J. R. Large-
387	Scale Proteomic Analysis of Follicular Lymphoma Reveals Extensive Remodeling of Cell
388	Adhesion Pathway and Identifies Hub Proteins Related to the Lymphomagenesis. Cancers
389	(Basel) 13 , (2021).
390	32. Dong, T. et al. The Expression of CD9 and PIK3CD is Associated with Prognosis of Follicular
391	Lymphoma. <i>J Cancer</i> 6 , 1222–1229 (2015).
392	33. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature
393	502 , 333–339 (2013).
394	34. Rheinbay, E. et al. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes.
395	Nature 578 , 102–111 (2020).

- 396 35. Lei, L. et al. Functions and regulatory mechanisms of metastasis-associated lung
- adenocarcinoma transcript 1. J Cell Physiol 234, 134–151 (2018).
- 398 36. Wang, Y. *et al.* TGF-β-induced STAT3 overexpression promotes human head and neck
- 399 squamous cell carcinoma invasion and metastasis through malat1/miR-30a interactions.
- 400 *Cancer Lett* **436**, 52–62 (2018).
- 401 37. Zheng, T., Ma, G., Tang, M., Li, Z. & Xu, R. IL-8 Secreted from M2 Macrophages Promoted
- 402 Prostate Tumorigenesis via STAT3/MALAT1 Pathway. Int J Mol Sci 20, (2018).
- 403 38. Stevenson, F. K., Forconi, F. & Kipps, T. J. Exploring the pathways to chronic lymphocytic
- 404 leukemia. *Blood* **138**, 827–835 (2021).
- 405 39. Arun, G., Aggarwal, D. & Spector, D. L. MALAT1 Long Non-Coding RNA: Functional
- 406 Implications. *Noncoding RNA* **6**, (2020).
- 407 40. Tauzin, S., Ding, H., Burdevet, D., Borisch, B. & Hoessli, D. C. Membrane-associated signaling in
- 408 human B-lymphoma lines. *Exp Cell Res* **317**, 151–162 (2011).

410

411

412 Statements & Declarations

413 Acknowledgements

414 This research was funded by Ministerio de Ciencia e Innovación (MCI), grant numbers RTI2018-094274-B-I00 to EC.; Fundació La Marato de TV3 ("projecte financat 415 416 per Fundació La Marató de TV3") 201920-30 to LH. Suport Grups de Recerca AGAUR 417 2014-SGR-795 and 2017-SGR-736 of the Generalitat de Catalunya to EC and JIM-S., respectively. AGAUR 2018 FIB00696, Generalitat de Catalunya to EMF-G. EC and JIM-S 418 419 are Academia Researchers of the "Institució Catalana de Recerca i Estudis Avançats" 420 (ICREA) of the Generalitat de Catalunya. We are indebted to the Genomics core facility of the Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS). 421

422

423 Authors' contributions

424 Conceived and designed the Study: Lluís Hernández and Elías Campo. Collected and processed clinical/expression data from ICGC, Hospital Clinic de Barcelona and GEO: 425 Elena María Fernández-Garnacho, Ferran Nadeu, Pablo Mozas, Andrea Rivero, Julio 426 427 Delgado, Eva Giné, Armando López-Guillermo, Martí Duran-Ferrer, Itziar Salaverria, 428 Cristina López, Sílvia Beà, Santiago Demajo, Pedro Jares, Xose S Puente and Lluís Hernández; Processed FFPE material from FL samples for RNA purification: Silvia Martín. 429 Analyzed the RNAseq/microarrays/qRT-PCR data and performed the statistical analysis: 430 Elena María Fernández-Garnacho, Ferran Nadeu, Pablo Mozas, Andrea Rivero and Lluís 431

432 Hernández wrote the manuscript: Elena María Fernández-Garnacho, Lluís Hernández,

433 Elías Campo and José Ignacio Martín-Subero. All authors read and approved the final

434 manuscript.

435 Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

438

439 Competing interests

440 The authors declare that they have no competing interests.

441

442 Ethics approval and consent to participate

Samples from FL patients were obtained from the Hematopathology collection of 443 the Biobank of the Hospital Clínic de Barcelona-IDIBAPS (Spain). RNAseq data and full 444 445 clinical annotations from CLL patients were obtained from the Spanish ICGC consortium, 446 which had an approval of the Institutional Review Board of Hospital Clinic de Barcelona, in 447 accordance with national regulations and the Declaration of Helsinki. All patients provided written informed consent. The remaining data from other samples were obtained from 448 449 GEO microarray public repository including previously published works with their particular 450 ethical compliances stated in the original articles.

451

452

453

454

455 Figure legends

456 Figure 1. MALAT1 expression levels in MBL, CLL molecular subgroups, and relationship to time to treatment (TTT). (a) MALAT1 expression was higher in CLL 457 patients than in MBL (P<0.001). Dotted line indicates the threshold of MALAT1 that 458 determines differences in outcome. No significant differences were observed in MALAT1 459 expression between CLL subgroups defined by IGHV mutational status (M-CLL versus U-460 461 CLL) (bottom left panel) or epigenetic subtypes (n-CLL: naïve-like, m-CLL: memory-like 462 and i-CLL: intermediate) (bottom right panel). (b) CLL patients with high MALAT1 expression showed significantly shorter TTT compared to those with low levels in the 463 global cohort (top panel), and almost every one of the different CLL subgroups related to 464 465 the IGHV mutational status (bottom left) and epigenetic subtypes (bottom right).

Figure 2. MALAT1 expression is an independent prognostic factor and is related to 466 relevant pathways in CLL. (a) Plot for multivariate model analyses, where MALAT1 467 468 expression as a continuous variable shows its independent prognostic value considered together with Binet stage and IGHV mutational status (left panel) or epigenetic subtypes 469 470 (right panel). For epigenetic groups, m-CLL was taken as a reference. (b) Summary of most relevant significant pathway enrichments found using Metascape tool regarding 471 472 coding genes positively (top panel) and negatively (bottom panel) correlated with MALAT1 473 expression in CLL subtypes defined by IGHV mutational status. Only statistically

474 significant Reactome pathways after multiple comparison correction are shown for475 compact representation.

Figure 3. *MALAT1* levels correlate with many genes that are upregulated in LN compared to PB CLL samples, whereas its expression was comparable in both anatomical compartments. (a) GSEA analysis shows that the nodal CLL signature (see material and methods) was significantly enriched in coding genes correlated with *MALAT1* expression in PB CLL samples of M-CLL and U-CLL subtypes. (b) No significant differences in *MALAT1* expression between paired PB and LN tissues (GSE21029) were observed.

Figure 4. *MALAT1* expression is associated with a more aggressive behavior and is related to pathogenetic pathways in FL. a. Kaplan-Meier curves for progression-free survival (PFS) according to *MALAT1* expression in FL. Patients with high *MALAT1* expression had a significantly shorter PFS than those with low levels. b. Summary of most relevant significant pathway enrichments among coding genes positively correlated with *MALAT1* in FL samples. Only statistically significant Reactome pathways after multiple comparison correction are shown for compact representation.

490

491 Supplementary Figure Legends

Fig.S1. (a) Optimal cut-off established by *maxstat* algorithm regarding *MALAT1*expression and TTT in CLL. (b) Optimal cut-off established by *maxstat* algorithm regarding *MALAT1* expression and OS in CLL.

Fig.S2. (a) Binet A CLL cases with high *MALAT1* expression had a significantly shorter
TTT than those with low levels. (b) No difference in OS was detected in all CLL cases with

high or low *MALAT1* expression neither using the same cutoff defining significant
differences for TTT (see Suppl. Fig1b) nor the optimal for OS (data not shown). (c) TTT
and *MALAT1* expression levels in IGHV-mutated and unmutated Binet A CLL cases. (d)
TTT and *MALAT1* expression levels in Binet A CLL epigenetic subtypes.

Fig.S3. (a) Similar *MALAT1* levels in CLL cases with a different number of genetic alterations. **(b)** No significant differences in *MALAT1* expression comparing CLL cases with (mutated) or without (wild-type) individual gene alterations after correction for multiple comparisons. **(c)** No significant differences in *MALAT1* expression comparing CLL cases with (altered) or without (wild-type) individual chromosomal alterations after correction for multiple comparisons.

Fig.S4. (a) Boxplot showing the distribution of the values of the three epiCMIT indexes in the three epigenetic groups of CLL cases analyzed according to the *MALAT1* expression categories. No significant differences were found in any comparison. **(b)** Scatterplots showing the linear correlation analyses between the three epiCMIT indexes and *MALAT1* expression values, in the three CLL epigenetic subtypes. None of these correlations were statistically significant.

Fig.S5. Summary of most relevant significant pathway enrichments found using Metascape tool involving signatures previously related to CLL pathogenesis and poor prognosis. Separated analyses were performed involving coding genes positively (top panel) and negatively (bottom panel) correlated with *MALAT1* expression in the different epigenetic CLL subtypes. Only statistically significant Reactome pathways after multiple comparison correction are shown for compact representation.

- 519 Fig.S6. (a) Kaplan-Meier curve showing the lack of significant differences in OS of FL
- 520 cases regarding *MALAT1* expression. (b) Cumulative incidence curves showing the lack
- 521 of significant differences regarding *MALAT1* expression and the risk of transformation.
- 522 Fig.S7. Venn diagram showing the overlapping between FL and CLL of MALAT1-
- 523 correlated genes in pathways found significantly enriched in separated analysis.






Figure 2





(b)


Enriched pathways in positively correlated genes with MALAT1 (CLL)











(b)






Figure 4



(b)

Enriched pathways in positively correlated genes with MALAT1 (FL)



M Phase MAPK family signaling cascades Signaling by the B Cell Receptor (BCR) Signaling by VEGF Interleukin-2 family signaling Cell Cycle, Mitotic Cell Cycle Interleukin-3, Interleukin-5 and GM-CSF signaling Signaling by Interleukins Cytokine Signaling in Immune system